Compare TCI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | LUNG |
|---|---|---|
| Founded | 1983 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 57.9M |
| IPO Year | 1994 | 2020 |
| Metric | TCI | LUNG |
|---|---|---|
| Price | $34.85 | $1.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 2.4K | ★ 511.9K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | 7.64 |
| EPS | ★ 0.02 | N/A |
| Revenue | $49,060,000.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $1,729.00 | ★ N/A |
| Revenue Growth | 4.23 | ★ 8.01 |
| 52 Week Low | $31.48 | $1.13 |
| 52 Week High | $59.65 | $3.88 |
| Indicator | TCI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 50.04 |
| Support Level | $33.50 | $1.27 |
| Resistance Level | $38.38 | $1.45 |
| Average True Range (ATR) | 0.91 | 0.09 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 17.52 | 55.56 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.